Tirosina quinasa / adaptadores
Los inhibidores de tirosina quinasa y adaptadores son compuestos que se dirigen a las tirosina quinasas y sus proteínas adaptadoras asociadas, las cuales desempeñan roles cruciales en la señalización celular, el crecimiento y la diferenciación. Estos inhibidores son herramientas esenciales en la investigación del cáncer, ya que muchas tirosina quinasas están involucradas en las vías de señalización que impulsan el crecimiento tumoral y la metástasis. Al inhibir las tirosina quinasas, estos compuestos pueden bloquear cascadas de señalización críticas, ofreciendo potenciales estrategias terapéuticas para varios tipos de cáncer y otras enfermedades que implican una señalización celular anormal. En CymitQuimica, ofrecemos una amplia gama de inhibidores de tirosina quinasa y adaptadores de alta calidad para apoyar su investigación en oncología, biología molecular y desarrollo de terapias dirigidas.
Subcategorías de "Tirosina quinasa / adaptadores"
- ALK(112 productos)
- CSF-1R(42 productos)
- EGFR(572 productos)
- Receptor de efrina(23 productos)
- FLT(92 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- HER(5 productos)
- Hck(3 productos)
- IGF-1R(88 productos)
- PDGFR(126 productos)
- PYK2(7 productos)
- Src(79 productos)
- Receptor TAM(32 productos)
- Tie-2(20 productos)
- Receptor de Trk(59 productos)
- Tirosina quinasas(26 productos)
- VEGFR(268 productos)
- c-Fms(108 productos)
- c-Kit(101 productos)
- c-Met / HGFR(128 productos)
- c-RET(51 productos)
Mostrar 13 subcategorías más
Se han encontrado 1370 productos de "Tirosina quinasa / adaptadores"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
SST0116CL1
CAS:<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Fórmula:C22H31ClN4O6Forma y color:SolidPeso molecular:482.96Lucitanib dihydrochloride
CAS:<p>Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient VEGFR1-3, FGFR1-3, and PDGFRalpha/β inhibitor, used in metastatic breast cancer research.</p>Fórmula:C26H27Cl2N3O4Forma y color:SolidPeso molecular:516.42ROS1-IN-2
CAS:<p>ROS1-IN-2 (Compound 3), a ROS1 inhibitor, is utilized in cancer research.</p>Fórmula:C29H37ClN5O2PForma y color:SolidPeso molecular:554.06HER2-IN-12
<p>HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.</p>Fórmula:C17H18BrN5O2SForma y color:SolidPeso molecular:436.33EGFR/HER2-IN-4
<p>EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.</p>Forma y color:Solid8-Br-cGMP-AM
CAS:<p>8-Br-cGMP-AM, a derivative of 8-Br-cGMP, acts as an activator of PKG (cGMP-dependent protein kinase), inducing various biological effects such as vasodilation and platelet inhibition. This compound is utilized in the research of cardiovascular diseases.</p>Fórmula:C13H15BrN5O9PForma y color:SolidPeso molecular:496.16EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Fórmula:C14H11BrN4O2SForma y color:SolidPeso molecular:379.23TRK-IN-28
CAS:TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].Fórmula:C27H25F2N7Forma y color:SolidPeso molecular:485.53TrkA-IN-7
CAS:<p>TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.</p>Fórmula:C16H13N3O3Forma y color:SolidPeso molecular:295.293JBJ-02-112-05
CAS:<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Fórmula:C27H20N4O2SPureza:98%Forma y color:SolidPeso molecular:464.54KRC-00715
CAS:<p>KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.</p>Fórmula:C25H25F3N8O3Forma y color:SolidPeso molecular:542.51TRK-IN-26
CAS:<p>TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].</p>Fórmula:C30H22F2N6O4Forma y color:SolidPeso molecular:568.53BTK-IN-16
CAS:<p>BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.</p>Fórmula:C15H14N4O2Pureza:99.04%Forma y color:SoildPeso molecular:282.3AZ8010
CAS:AZ8010 (AZ12908010) serves as an effective inhibitor of FGFR1-3 and exhibits antiproliferative properties, making it useful for cancer research.Fórmula:C27H34N4O3Forma y color:SolidPeso molecular:462.58HER2-IN-8
CAS:<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Fórmula:C26H25F2N9O3Forma y color:SolidPeso molecular:549.53EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Fórmula:C21H23N3O5Forma y color:SolidPeso molecular:397.424EGFR-IN-38
CAS:<p>EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.</p>Fórmula:C25H24ClN7O2Forma y color:SolidPeso molecular:489.96EGFR-IN-126
CAS:<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Fórmula:C28H28BrFN4O3Forma y color:SolidPeso molecular:567.45BTK-IN-38
CAS:<p>BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.</p>Fórmula:C27H26F2N4O2Forma y color:SolidPeso molecular:476.52BNN-20
CAS:<p>BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.</p>Fórmula:C20H30O2Forma y color:SolidPeso molecular:302.45MerTK/Axl-IN-1
CAS:<p>MerTK/Axl-IN-1 (Compound A-910) is a potent and selective dual inhibitor of MerTK/Axl, exhibiting IC50 values of 4.2 nM and 8.8 nM in Ba/F3 cells, and 0.2 nM and 0.9 nM in HTRF cells, respectively. It effectively inhibits pMerTK in vivo and possesses a long half-life and high oral bioavailability.</p>Fórmula:C40H47FN6O4Forma y color:SolidPeso molecular:694.84c-Kit-IN-8
CAS:<p>C-Kit-IN-8 (Compound 53) acts as an inhibitor of c-Kit kinase, hampering uKIT kinase activity with an IC50 greater than 1 μM. Additionally, it inhibits the proliferation of both wild-type and mutant GIST430 and BaF3 cancer cells, exhibiting an IC50 greater than 0.1 μM.</p>Fórmula:C24H26FN5O4Forma y color:SolidPeso molecular:467.49EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Fórmula:C12H14N4OS2Forma y color:SolidPeso molecular:294.4EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Fórmula:C24H15FO3Forma y color:SolidPeso molecular:370.37CL-A3-7
CAS:<p>CL-A3-7 is a viral-cell fusion inhibitor targeting the RSVF protein. It functions by blocking the interaction between the virus and the host's IGF1R, effectively inhibiting the infection of both wild-type and K394R mutant strains of RSV. This compound is suitable for use in antiviral drug development and resistance studies related to RSV.</p>Fórmula:C24H22Br2F2N2O3Forma y color:SolidPeso molecular:584.25TAS05567
CAS:<p>TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).</p>Fórmula:C21H29N9O2Pureza:98%Forma y color:SolidPeso molecular:439.51DYRKs-IN-1
CAS:<p>DYRKs-IN-1 has antitumor activity.</p>Fórmula:C30H30ClN7O4Pureza:98%Forma y color:SolidPeso molecular:588.062-Methyl-3-phenylquinoxaline
CAS:<p>2-Methyl-3-phenylquinoxaline (compound 38) serves as an effective inhibitor of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase (PDGF-RTK), exhibiting significant inhibitory activity against the full-length PDGFR kinase in intact cells (IC50 greater than 100 μM).</p>Fórmula:C15H12N2Forma y color:SolidPeso molecular:220.27BIIB129
CAS:<p>BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.</p>Fórmula:C19H22N6O2Pureza:98.56%Forma y color:SolidPeso molecular:366.42D-69491 hydrochloride
CAS:<p>D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.</p>Fórmula:C25H26Cl2FN7O3Forma y color:SolidPeso molecular:562.42Pred17
<p>Pred17 is an effective EGFR inhibitor with potential applications in lung cancer research.</p>Fórmula:C27H22BN3OForma y color:SolidPeso molecular:415.29ES-072
CAS:<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Fórmula:C25H27F3N8O2Forma y color:SolidPeso molecular:528.53BPI-15086
CAS:<p>BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.</p>Fórmula:C29H33ClN8O4Forma y color:SolidPeso molecular:593.08NMS-P626
CAS:<p>NMS-P626 functions as an inhibitor targeting TRKA, TRKB, and TRKC, exhibiting IC 50 values of 8 nM, 7 nM, and 3 nM respectively. It effectively suppresses KM12 cell growth by inhibiting the phosphorylation of TPM3-TRKA and the subsequent downstream signaling, demonstrating an IC 50 of 19 nM specifically for KM12 cells. This compound is applicable in the study of colorectal cancer.</p>Fórmula:C28H35F2N7O4SForma y color:SolidPeso molecular:603.68Neptinib
CAS:<p>Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.</p>Fórmula:C22H23ClFN5O2Forma y color:SolidPeso molecular:443.90HS-345
CAS:<p>HS-345, a TrkA/Akt inhibitor, exhibits potent anti-pancreatic cancer properties. This compound inhibits the growth and proliferation of pancreatic cancer cells by blocking the TrkA/Akt signaling pathway and induces cell apoptosis (Apoptosis). Additionally, HS-345 inhibits angiogenesis by reducing the expression of HIF-1α and VEGF. It holds promise for use in pancreatic cancer research.</p>Fórmula:C19H18N6O2SForma y color:SolidPeso molecular:394.45EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Fórmula:C30H35FN6O3Forma y color:SolidPeso molecular:546.64PET-cGMP
CAS:<p>PET-cGMP is an analogue of cyclic guanosine monophosphate and functions as a potent, selective agonist for PKGI. It exhibits an EC50 of 3.8 nM for PKGIβ and 193 nM for PKGII.</p>Fórmula:C18H16N5O7PForma y color:SolidPeso molecular:445.323HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Fórmula:C26H32N8O3Forma y color:SolidPeso molecular:504.58EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Fórmula:C26H27ClN6O2Forma y color:SolidPeso molecular:490.98EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Fórmula:C27H31ClN7O3PForma y color:SolidPeso molecular:568.01Sacibertinib
CAS:<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Fórmula:C32H31ClN6O4Forma y color:SolidPeso molecular:599.08EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Fórmula:C16H16N4O2SForma y color:SolidPeso molecular:328.39EGFR-IN-35
CAS:<p>EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.</p>Fórmula:C25H24ClN7O2Forma y color:SolidPeso molecular:489.96EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Fórmula:C33H28N6O3SForma y color:SolidPeso molecular:588.68EGFR-IN-23
CAS:<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Fórmula:C36H44BrN10O3PForma y color:SolidPeso molecular:775.68Vecabrutinib
CAS:<p>Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.</p>Fórmula:C22H24ClF4N7O2Pureza:99.74%Forma y color:SolidPeso molecular:529.92Zotizalkib
CAS:<p>TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.</p>Fórmula:C21H20F3N5O3Pureza:98.7%Forma y color:SolidPeso molecular:447.41AZ12601011
CAS:<p>AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.</p>Fórmula:C19H15N5Pureza:98.81%Forma y color:SolidPeso molecular:313.36Enbezotinib
CAS:<p>Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.</p>Fórmula:C21H21FN6O3Pureza:99.84%Forma y color:SolidPeso molecular:424.43AGL-2263
CAS:<p>AGL-2263 is a blocker of insulin receptor (IR)</p>Fórmula:C17H10N2O5Forma y color:SolidPeso molecular:322.27EGFR-IN-7
CAS:<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Fórmula:C32H41BrN9O2PPureza:95.32% - 99.64%Forma y color:SolidPeso molecular:694.6HMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Forma y color:Odour LiquidTyrosine kinase inhibitor
CAS:<p>Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.</p>Fórmula:C31H31FN6O5Pureza:98%Forma y color:SolidPeso molecular:586.61Nimotuzumab (powder)
CAS:<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Forma y color:LiquidTLC9995-0188
CAS:<p>Tyrosine-protein kinase ABL, IC50: 1500 nM</p>Fórmula:C16H15N5Forma y color:Yellow SolidPeso molecular:277.331Duligotuzumab
CAS:<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Pureza:95%Forma y color:LiquidRef: TM-T80604
Producto descatalogadoEGFR-IN-82
CAS:<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Fórmula:C32H41BrN9O2PPureza:98%Forma y color:SolidPeso molecular:694.6Ref: TM-T78788
Producto descatalogadoTrk-IN-4
CAS:<p>Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.</p>Fórmula:C24H23F4N5O4Pureza:98.13%Forma y color:SolidPeso molecular:521.46FGFR1 inhibitor-10
CAS:<p>FGFR1 inhibitor-10 (Compound 4i), with an IC50 of 28 nM, effectively inhibits FGFR1 phosphorylation.</p>Fórmula:C26H30F3N7O2SPureza:98%Forma y color:SolidPeso molecular:561.62Ref: TM-T79686
Producto descatalogadoAPG-2449
CAS:<p>APG-2449 is an orally active inhibitor targeting ALK, ROS1, and FAK, demonstrating antitumor efficacy in mouse models of non-small cell lung cancer (NSCLC) [1].</p>Fórmula:C33H42ClN5O4SPureza:98%Forma y color:SolidPeso molecular:640.24Ref: TM-T79363
Producto descatalogadoJDB175
CAS:<p>JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.</p>Fórmula:C26H21F3N4O2Pureza:98%Forma y color:SolidPeso molecular:478.47YK-029A
CAS:<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Fórmula:C27H32N8O2Pureza:98%Forma y color:SolidPeso molecular:500.6Ref: TM-T79461
Producto descatalogadoBTK-IN-27
CAS:<p>BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.</p>Fórmula:C31H35N7O2Pureza:98%Forma y color:SolidPeso molecular:537.66Syk-IN-8
CAS:<p>Syk-IN-8 (compound 19q) functions as a Syk inhibitor with demonstrated antiproliferative effects on a variety of hematological tumor cells.</p>Fórmula:C23H26N10Pureza:98%Forma y color:SolidPeso molecular:442.52TrkB-IN-1
CAS:<p>TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.</p>Fórmula:C19H16N2O6Pureza:98%Forma y color:SolidPeso molecular:368.34Canlitinib
CAS:<p>Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.</p>Fórmula:C33H31F2N3O7Pureza:98%Forma y color:SolidPeso molecular:619.61BTK-IN-25
CAS:<p>BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].</p>Fórmula:C28H27F2N3O5Pureza:98%Forma y color:SolidPeso molecular:523.53EGFR-IN-122
CAS:<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Fórmula:C19H20N4O3Forma y color:SolidPeso molecular:352.39Ref: TM-T200157
Producto descatalogadoEGFR-IN-123
CAS:<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Fórmula:C24H27F3N6OForma y color:SolidPeso molecular:472.51Ref: TM-T200485
Producto descatalogado
